Latest updates
December 16: Illumina has criticized EU regulators in court for the Commission’s scrutiny of its acquisition of Grail.
August 18: US biotech company Illumina acquires Grail, even though the European Commission has not completed its review of the acquisition.
April 20: In response to competition concerns, EU antitrust regulators will examine Illumina’s proposed acquisition of Grail.
March 30: The Federal Trade Commission has filed to block Illumina’s proposed acquisition of Grail.